Radiotheranostic Targeting Cancer Stem Cells in Human Colorectal Cancer Xenografts

• Published in: Molecular imaging and biology 2020-08, Vol.22 (4), p.1043-1053
• Main Authors: She, Xianliang, Qin, Saimei, Jing, Boping, Jin, Xueyan, Sun, Xun, Lan, Xiaoli, An, Rui
• Format: Article
• Language: English
• Subjects: Apoptosis; Biomarkers; Biotin; Cancer; CD44 antigen; Colorectal cancer; Colorectal carcinoma; Computed tomography; DNA nucleotidylexotransferase; Flow cytometry; Growth curves; Imaging; Immunoglobulin G; Immunohistochemistry; Medicine; Medicine & Public Health; Monoclonal antibodies; Photon emission; Radioactivity; Radiology; Research Article; Single photon emission computed tomography; Stem cell transplantation; Stem cells; Survival; Tomography; Tumors; Xenografts; Xenotransplantation
• ISSN: 1536-1632; 1860-2002
• DOI: 10.1007/s11307-019-01467-7

Purpose The aim of this study was to perform radiotheranostics with radioiodinated monoclonal antibodies (mAbs) for targeting cancer stem cells (CSCs) in human colorectal cancer xenografts and evaluate the relative advantage of a cocktail containing both [ 131 I]CD133 mAb and [ 131 I]CD44 mAb. Procedures Tumor-bearing mice were randomly divided into eight groups: [ 131 I]CD133mAb, [ 131 I]CD44 mAb, [ 131 I]IgG isotype control, radioiodinated mAb cocktail, CD133 mAb, CD44 mAb, unradioiodinated mAb cocktail, and saline groups. In vivo single photon emission computed tomography (SPECT) imaging was used to monitor dynamically changes in the CSC population after treatment. The radioactivity uptake of tumors was quantified ex vivo . The expression of CD133 and CD44 after treatment was also assessed by immunohistochemistry and western blot. Tumor growth curves and survival curves were generated to assess treatment efficacy. Cell apoptosis and proliferation in xenografts 30 days after treatment were measured by TdT-mediated dUTP-biotin nick end labeling (aka, TUNEL) and Ki67 staining. The expression levels of biomarkers in xenografts 30 days after treatment were measured by flow cytometry. Results The radioimmunoimaging (RII) with in vivo SPECT showed that the CSC-targeting radioimmunotherapy (RIT) groups ([ 131 I]CD133 mAb, [ 131 I]CD44 mAb, and radioiodinated mAb cocktail groups) had intense accumulations of radiolabeled agents in the tumor areas. The ex vivo biodistribution confirmed these findings. In the CSC-targeting RIT groups, immunohistochemistry and western blot indicated significant reduction of specific target expression in the xenografts. The tumor growth curves and survival curves showed that the CSC-targeting RIT significantly inhibited tumor growth and prolonged mean survival, respectively. Significantly increased apoptosis and decreased proliferation in xenografts further confirmed the therapeutic efficacy of CSC-targeting RIT. Flow cytometry showed that the decreases in CSCs correlated with the presence of the corresponding antibodies. Conclusions Our results suggest that the CSC-targeting RIT can effectively reduce CSCs which consequently inhibits tumor development. The radioiodinated mAb cocktail may generate enhanced CSC-targeting specificity.